Results 221 to 230 of about 131,242 (269)

Efficacy and safety of combining empagliflozin in people with type 2 diabetes mellitus uncontrolled with metformin and sitagliptin: A randomised, double‐blind, multicentre, therapeutic confirmatory phase 3 clinical trial

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aim This study evaluated the efficacy and safety of empagliflozin 10 and 25 mg compared to placebo as add‐on treatment for people with type 2 diabetes mellitus (T2DM) uncontrolled after ≥8 weeks of treatment with metformin and sitagliptin. Materials and Methods A randomised, double‐blind, multicentre, therapeutic confirmatory, phase 3 clinical
Seung‐Hwan Lee, Kyung Ah Han, Eun‐Gyoung Hong, Jun Goo Kang, Choon Hee Chung, Jong Chul Won, Eon Ju Jeon, Jung‐Hwan Cho, Ho Chan Cho, Sin Gon Kim, Eun Seok Kang, So Hun Kim, Hae Jin Kim, In‐Kyung Jeong, Sung Wan Chun, Young Min Cho   +15 more
wiley   +1 more source

Shift in secretory profile of a pNET: from indolent glucagonoma to aggressive insulinoma - a case report. [PDF]

Front Endocrinol (Lausanne)
Gil Dos Santos S, Calheiros R, Oliveira J, Santos AP, Souteiro P.   +4 more
europepmc   +1 more source

Modeling the Glucose-Insulin-Glucagon Interactions

Salma Al-Tuwairqi, Khlood Alamer, Hunida Malaikah   +2 more
openalex   +2 more sources

Mental health changes after 4 months of weight loss treatment with the glucagon‐like peptide‐1 analogue liraglutide 3.0 mg

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Objective This observational study examined changes in mental health and wellbeing after 4‐months liraglutide 3.0 mg treatment in patients with obesity and explored associations with weight loss. Methods We included 98 patients with obesity treated with liraglutide 3.0 mg.
Susanne Kuckuck, Nina van Gerwen, Johanneke E. Oosterman, Mesut Savas, Maryam Kavousi, Brenda W. J. H. Penninx, Mariëtte R. Boon, Elisabeth F.C. van Rossum   +7 more
wiley   +1 more source

Long‐acting insulin analogues and the risk of diabetic nephropathy among patients with type 2 diabetes: A population‐based cohort study

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims The risk of diabetic nephropathy among patients with type 2 diabetes (T2D) can be reduced through optimal glycaemic control. It is not known if the pharmacological properties of long‐acting insulin analogues may reduce the risk of diabetic complications compared with neutral protamine Hagedorn (NPH) insulin.
Julia Brillinger, Christopher Filliter, Shahrzad Salmasi, Estefania Zapata‐Bravo, Robert W. Platt, Oriana H. Y. Yu, Kristian B. Filion   +6 more
wiley   +1 more source

Glucagon-like peptide1 receptor agonist treatment of cystic fibrosis-related diabetes complicated by obesity: A cases series and literature review

Ammar Ahmed, Anvitha Ankireddypalli, Tasma Harindhanavudhi, Antoinette Moran, Amir Moheet   +4 more
openalex   +1 more source

Chronically elevated sympathetic nervous system tone: A significant, common, and poorly realised contributor to cardiometabolic disease in type 2 diabetes

Diabetes, Obesity and Metabolism, EarlyView.
Ralph A. DeFronzo
wiley   +1 more source

Beyond diabetes and obesity: GLP‐1 receptor agonists in disrupting the vicious cycle of metabolic dysfunction and neuroinflammation

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Neurodegenerative diseases, including debilitating conditions like Alzheimer's and Parkinson's, are characterized by progressive neuronal loss, a process fundamentally driven by persistent chronic neuroinflammation and central metabolic dysfunction.
Renata Spezani, Carlos A. Mandarim‐de‐Lacerda   +1 more
wiley   +1 more source

Preoperative Glucagon-Like Peptide-1 Receptor Agonist Treatment to Allow Safe Laparoscopic Left Pancreatectomy in Extreme Obesity: The First Report. [PDF]

Case Rep Surg
Canali G, Herfeld G, Averous G, Baltzinger P, Addeo P.   +4 more
europepmc   +1 more source